Roivant Sciences Ltd.
ROIV
$10.66
$0.242.30%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 169.38M | -- | 95.30M | -151.12M | 5.10B |
| Total Depreciation and Amortization | 1.94M | -- | 4.88M | 5.23M | 2.52M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -325.47M | -- | -212.01M | 21.48M | -5.33B |
| Change in Net Operating Assets | -53.11M | -- | -81.00M | 15.96M | 21.20M |
| Cash from Operations | -207.25M | -- | -192.83M | -108.46M | -210.45M |
| Capital Expenditure | -1.83M | -- | -965.00K | -349.00K | -355.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 154.44M | -- | -- | -804.00K | 5.23B |
| Other Investing Activities | 301.46M | -- | -- | 8.08M | 0.00 |
| Cash from Investing | 454.07M | -- | -965.00K | 6.93M | 5.23B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -49.09M | -- | -1.83M | -7.67M | -7.66M |
| Issuance of Common Stock | 28.12M | -- | 2.27M | 3.66M | 8.88M |
| Repurchase of Common Stock | -251.98M | -- | -661.06M | -28.61M | -3.31M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | 238.73M |
| Cash from Financing | -272.95M | -- | -660.62M | -32.62M | 236.64M |
| Foreign Exchange rate Adjustments | -1.07M | -- | -2.74M | -855.00K | 3.04M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -27.20M | -- | -857.15M | -135.01M | 5.26B |
